4SC AG said that its cancer therapy, resminostat, in combination with sorafenib, achieved a progression-free survival of 4.7 months after 12 weeks in patients with advanced liver cancer. Data will be presented at ASCO on 4 June. ---Subscribe to MedNous to access this article--- Company News Research & University News
